Revolutionising Prostate Cancer Treatment: Shorter, Sharper Radiotherapy Comes to the NHS
England is set to embrace a significant advancement in prostate cancer care, with thousands of men being offered a new, highly targeted form of radiotherapy. This cutting-edge treatment, known as Stereotactic Ablative Body Radiotherapy (SABR), promises to dramatically reduce the number of treatment sessions required, from over 20 down to just five.
SABR represents a powerful and precise approach to fighting early-stage prostate cancer. Its effectiveness lies in its ability to deliver higher doses of radiation in a concentrated manner, meaning fewer visits to the hospital. This focused delivery also significantly minimises damage to surrounding healthy tissues, thereby reducing the likelihood of side effects and curbing the potential for the tumour to grow or spread. The technology works by directing radiation beams from multiple angles, meticulously targeting the cancerous cells while sparing nearby organs and tissues.
NHS England has confirmed that all 48 radiotherapy centres across the country will begin offering SABR to eligible men diagnosed with early prostate cancer within the next three months. Some facilities are expected to commence this new treatment as early as next week, signalling a swift implementation of this promising innovation.
The typical SABR regimen involves five doses administered over a two-week period. This stands in stark contrast to conventional radiotherapy, which often necessitates 20 or more sessions, highlighting the substantial improvement in convenience and reduced patient burden.
Who Will Benefit?
It is estimated that around 17,500 men diagnosed annually with low or intermediate-risk prostate cancer in England could be eligible for this new treatment. Modelling conducted by NHS England suggests that a substantial proportion of these men, potentially nearly a fifth (approximately 3,500 individuals), may opt for SABR. It’s important to note that many men diagnosed with early prostate cancer currently choose active surveillance, a strategy involving close monitoring of the cancer until it shows signs of progression or potential harm.
Transforming Patient Experience
NHS chief executive Sir Jim Mackey hailed the introduction of SABR as a transformative development for prostate cancer patients. “This cutting-edge approach will transform treatment for thousands of men with prostate cancer, helping the NHS provide far more powerful and convenient care to stop their cancer spreading,” he stated.
Sir Jim elaborated on the benefits, highlighting that the technology is not only proven effective in controlling cancer but also contributes to a reduction in certain side effects. Crucially, it alleviates the significant “to-and-fro” burden of frequent hospital visits, which he acknowledged can be incredibly draining for patients and their families.
Professor Peter Johnson, NHS national clinical director for cancer, underscored the precision of SABR. “This technology lets us focus a powerful and precise beam of radiotherapy directly on to the cancer, limiting the damage to healthy cells – and the fact it can be delivered in 15 fewer doses will help men get back to living their lives far more quickly,” he explained.
Professor Johnson also emphasised the significance of making this pioneering treatment widely available on the NHS, especially given that its development was significantly driven by UK-led trials. He advised that while SABR is not suitable for all individuals with localised prostate cancer, anyone with questions about their treatment options should consult their specialist team.
Impact on Waiting Lists and Future Research
Prostate cancer is a significant health concern in the UK, being the most common cancer among men. Over 55,000 men are diagnosed with the disease each year, and tragically, around 12,300 succumb to it annually.
The rollout of SABR is projected to have a considerable impact on hospital capacity. NHS England estimates that this new treatment could free up approximately 50,000 appointments for prostate cancer treatment each year, a development that could significantly contribute to reducing waiting lists.
Amy Rylance, director of health services at Prostate Cancer UK, expressed strong support for the initiative. “It means men will go from needing 20 hospital trips in quick succession to just five, massively reducing the burden that cancer places on them and their loved ones,” she commented.
Prostate Cancer UK, as the UK’s largest public funder of prostate cancer research, expressed pride in their role in substantiating the safety and efficacy of SABR. The organisation is now investing further to explore the potential of SABR for an even broader group of patients, including those whose cancer has begun to spread beyond the prostate.
“This would completely shift the paradigm in prostate cancer treatment, allowing us to cure cancers that would today be described as incurable,” Ms. Rylance added, pointing towards a future where even more advanced cases might be treatable with advanced radiotherapy techniques.
